Systematic review of obesity control with cannabidiol use: major current aspects

Introduction: There are 2.0 billion overweight and obese people in the world, and Brazil is in fifth place in the world ranking. In this context, a factor associated with an eating disorder is anxiety. In this sense, cannabidiol (CBD) showed anxiolytic, antipsychotic, neuroprotective symptoms, anti-inflammatory, and antiemetic properties. Objective:Wasto analyze through a systematic review the main considerations and results in animal and human models of cannabidiol use in obesity control. Methods: The model followed for the systematic review was PRISMA. The search strategy was performed in the PubMed, Embase, Ovid and Cochrane Library, Web Of Science, Science Direct Journals and Scopus. Main findings: In the context of increase in the incidence of obese people, activation of CB1 receptors improves diet by modulating the activity of hypothalamic neurons and, subsequently, the release of orexigenic and anorectic neuropeptides. Thus, in obesity, the endocannabinoid system (ECS) is usually down-regulated in central and peripheral tissues, as indicated by high and/or overexpression of the CB1 receptor. Therefore, CBD has been shown to be beneficial for anxiety-related disorders. Thus, CBD has been shown to have anxiolytic, antipsychotic and neuroprotective properties. Final Considerations: Increasing evidence indicates that CBD acts as antipsychotic and anxiolytic, and several reports suggest neuroprotective effects. In addition, CBD attenuates the detrimental effects of trans-Δ9-tetrahydrocannabinol, both acutely and chronically, including psychotogenic, anxiogenic, and deleterious cognitive effects.